| 李任,徐永,陈轼.肾衰宁胶囊治疗慢性肾衰竭钙磷代谢紊乱的临床研究[J].浙江中西医结合杂志,2019,29(3): |
| 肾衰宁胶囊治疗慢性肾衰竭钙磷代谢紊乱的临床研究 |
| Clinical study on the treatment of calcium and phosphorus metabolismdisorder in chronic renal failure by Shenshuaining Capsule |
| 投稿时间：2018-07-05 修订日期：2018-08-29 |
| DOI： |
| 中文关键词: 慢性肾衰竭 钙磷代谢紊乱 肾衰宁胶囊 营养状况 肾功能 |
| 英文关键词:chronic renal failure calcium and phosphorus metabolism disorder Shenshuaining Capsule nutritional status, renal function |
| 基金项目: |
|
| 摘要点击次数: 1202 |
| 全文下载次数: 16 |
| 中文摘要: |
| 目的 观察肾衰宁胶囊联合碳酸钙治疗慢性肾衰竭血液透析伴钙磷代谢紊乱患者的临床疗效及对患者血中相关生化指标的影响。方法 将132例慢性肾衰竭血液透析伴钙磷代谢紊乱患者随机分为对照组66例和试验组66例。对照组进行基础治疗；试验组在对照组的基础上服用肾衰宁胶囊,连续治疗2个月。比较2组患者的临床疗效、钙、磷、碱性磷酸酶、甲状旁腺激素指标、营养状况、肾功能及药物不良反应的发生情况。结果 治疗后,试验组患者总有效率为83.33%(55例/66例),对照组为65.15%(43例/66例),差异有统计学意义(P<0.05)。治疗后,试验组的钙、磷、碱性磷酸酶、甲状旁腺激素分别为(2.19±0.19)mmol.L-1,(1.81±0.20)mmol.L-1,(108.29±19.31)U.L-1,(368.48±43.70)pg.mL-1,对照组分别为(1.81±0.29)mmol.L-1,(2.12±0.25)mmol.L-1,(117.19±15.60)U.L-1,(459.74±41.66)pg.mL-1,差异有统计学意义(均P<0.05)。试验组患者治疗后血红蛋白、白蛋白、前白蛋白分别为(96.26±8.77)g.L-1,(35.91±5.31)g.L-1,(162.83±11.59)mg.L-1,均显著高于对照组的(83.06±9.17)g.L-1,(31.68±4.59)g.L-1,(104.11±9.71)mg.L-1(均P<0.05)。治疗后试验组患者BUN及Scr水平均显著下降,分别为(581.84±92.81)μmol.L-1和(23.84±4.29)mmol.L-1,与对照组的(709.44±82.38)μmol.L-1和(26.73±4.82)mmol.L-1比较,差异有统计学意义(均P<0.05)。2组患者治疗期间均未出现明显的药物不良反应。结论 肾衰宁胶囊联合碳酸钙对慢性肾衰竭血液透析伴钙磷代谢紊乱患者的疗效更加显著,有效调节慢性肾衰竭钙磷代谢紊乱,改善患者营养状况及肾功能。 |
| 英文摘要: |
| Objective To observe the clinical effect of Shenshuaining Capsule combined with calcium carbonate on correlated biochemical indexes in patients with calcium and phosphorus metabolism disorder in chronic renal failure (CRF). Methods One hundred and thirty-two patients with calcium and phosphorus metabolism disorder in CRF were randomly divided into control group (n=66) and treatment group (n=66). Control group was treated with regular treatment. Treatment group was given Shenshuaining Capsule for two months continuously. The clinical efficacy, Ca, P, alkaline phosphatase(ALP), Intact parathyroid hormone(iPTH), nutritional status, renal function, and the incidence of adverse drug reactions were observed in two groups. Results After treatment, total effective rates in treatment group and control group were 83.33% (55 cases/66 cases), 65.15%(43 cases/66 cases), with significant difference (P<0.05). After treatment, the levels of Ca, P, ALP, and iPTH in treatment group were (2.19±0.19)mmol.L-1, (1.81±0.20)mmol.L-1, (108.29±19.31)U.L-1, (368.48±43.70)pg.mL-1, had significant difference with those in control group, which were (1.81±0.29)mmol.L-1, (2.12±0.25)mmol.L-1, (117.19±15.60)U.L-1, (459.74±41.66)pg.mL-1 (P<0.05). After treatment, Hemoglobin(HGB), Albumin(ALB) and Prealbumin(PA) in treatment group were (96.26±8.77)g.L-1, (35.91±5.31)g.L-1, (162.83±11.59)mg.L-1, had significant difference with those in control group, which were (83.06±9.17)g.L-1, (31.68±4.59)g.L-1, (104.11±9.71)mg.L-1 (P<0.05). which reached to(35.19±5.26), (12.39±2.12)μg.mL-1 (P<0.05). Compared to control group, which were (709.44±82.38)μmol.L-1 and (26.73±4.82)mmol.L-1, the levels of BUN and Scr of patients in treatment group that decreased significantly to (581.84±92.81)μmol.L-1 and (23.84±4.29)mmol.L-1 had a significantly difference(P<0.05). There was no adverse drug reactions in two groups during the treatment. Conclusion Shenshuaining Capsule combined with calcium carbonate has significant effect in patients with calcium and phosphorus metabolism disorder in CRF, regulate the disorders of calcium and phosphorus metabolism disorder in chronic renal failure effectively and improve the renal function and nutritional status. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
